METACARDIS applies a systems medicine multilevel approach to identify biological relationships between gut microbiota, assessed by metagenomics, and host genome expression regulation, which will improve understanding and innovativ...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
BiomeDxRx
Microbiome-based diagnostics and therapeutics
150K€
Cerrado
METAMAPPER
Super resolution genomic mapping for the microbiome
150K€
Cerrado
SAF2014-52875-R
ESTUDIO METABOLOMICO DE LA INTERACCION HUESPED-MICROBIOTA IN...
194K€
Cerrado
SAF2009-13032-C02-01
METAGENOMICA POBLACIONAL DE COMUNIDADES MICROBIANAS HUMANAS
392K€
Cerrado
METAHIT
Metagenomics of the Human Intestinal Tract
21M€
Cerrado
PCI2018-093284
OBESIDAD Y DIABETES EN IBEROAMERICA: FACTORES DE RIESGO Y NU...
12K€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
METACARDIS applies a systems medicine multilevel approach to identify biological relationships between gut microbiota, assessed by metagenomics, and host genome expression regulation, which will improve understanding and innovative care of cardiometabolic diseases (CMD) and their comorbidities. CMD comprise metabolic (obesity, diabetes) and heart diseases characterized by a chronic evolution in ageing populations and costly treatments. Therapies require novel integrated approaches taking into account CMD natural evolution.
METACARDIS associates European leaders in metagenomics, who have been successful in establishing the structure of the human microbiome as part of the EU FP7 MetaHIT consortium, clinical and fundamental researchers, SME, patients associations and food companies to improve the understanding of pathophysiological mechanisms, prognosis and diagnosis of CMD.
We will use next-generation sequencing technologies and high throughput metabolomic platforms to identify gut microbiota- and metabolomic-derived biomarkers and targets associated with CMD risks. The pathophysiological role of these markers will be tested in both preclinical models and replication cohorts allowing the study of CMD progression in patients collected in three European clinical centres of excellence. Their impact on host gene transcription will be characterised in patients selected for typical features of CMD evolution. Application of computational models and visualisation tools to complex datasets combining clinical information, environmental patterns and gut microbiome, metabolome and transcriptome data is a central integrating component in the research, which will be driven by world leaders in metagenomic and functional genomic data analysis. These studies will identify novel molecular targets, biomarkers and predictors of CMD progression, paving the way for personalized medicine in CMD.